Tags

Type your tag names separated by a space and hit enter

Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism.
J Endocrinol Invest. 1998 Jun; 21(6):348-52.JE

Abstract

The aim of this study was to compare the clinical efficacy and safety of low dose cyproterone acetate-estrogen combination (Diane) and the 5 alpha-reductase inhibitor finasteride in the treatment of hirsutism. Fourty-two women with hirsutism were included in the study. Twenty-one patients treated with cyproterone acetate (CPA) 2 mg and ethinyl estradiol (E) 35 micrograms daily on days 5-25 of the menstrual cycle, 21 with finasteride 5 mg daily. Hirsutism score, hormone levels, multiscreen blood chemistry and side effects were evaluated at three-monthly intervals for 9 months. A significant decrease in hirsutism score as compared to baseline was observed after 9 months with either CPA + E (Diane) (mean +/- SE, 15.81 +/- 1.19 vs 8.38 +/- 1.21) or finasteride treatment (17.81 +/- 1.05 vs 10.86 +/- 0.91) (p < 0.0005). The reductions in hirsutism scores (mean% +/- SE) were 14.23 +/- 2.29 vs 19.77 +/- 2.22 (p < 0.05) at 3, 40.23 +/- 4.58 vs 29.49 +/- 2.69 (p < 0.02) at 6 and 50.99 +/- 4.13 vs 39.87 +/- 3.30 (p < 0.02) at 9 months in CPA + E and finasteride groups, respectively. No significant changes were observed in hormone levels during finasteride treatment. Serum free testosterone significantly decreased at the third month of treatment, and remained suppressed for the duration of treatment in CPA + E group. DHEAS levels also decreased significantly after 6 and 9 months of therapy with CPA + E. SHBG significantly increased during CPA + E treatment. We conclude that both drugs are effective and well tolerated, but CPA + E appears to be more effective than 5 alpha-reductase inhibitor finasteride in long-term treatment of hirsute women. Diane is also a cost-effective drug.

Authors+Show Affiliations

Sahin Y
Department of Obstetrics, Erciyes University, Faculty of Medicine, Kayseri, Turkey.
Bayram F
No affiliation info available
Keleştimur F
No affiliation info available
Müderris I
No affiliation info available

MeSH

5-alpha Reductase InhibitorsAndrogen AntagonistsCyproterone AcetateDrug Therapy, CombinationEnzyme InhibitorsEthinyl EstradiolFemaleFinasterideHirsutismHumansMenstrual CycleSex Hormone-Binding GlobulinTestosterone

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

9699125

Citation

Sahin, Y, et al. "Comparison of Cyproterone Acetate Plus Ethinyl Estradiol and Finasteride in the Treatment of Hirsutism." Journal of Endocrinological Investigation, vol. 21, no. 6, 1998, pp. 348-52.
Sahin Y, Bayram F, Keleştimur F, et al. Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. J Endocrinol Invest. 1998;21(6):348-52.
Sahin, Y., Bayram, F., Keleştimur, F., & Müderris, I. (1998). Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. Journal of Endocrinological Investigation, 21(6), 348-52.
Sahin Y, et al. Comparison of Cyproterone Acetate Plus Ethinyl Estradiol and Finasteride in the Treatment of Hirsutism. J Endocrinol Invest. 1998;21(6):348-52. PubMed PMID: 9699125.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. AU - Sahin,Y, AU - Bayram,F, AU - Keleştimur,F, AU - Müderris,I, PY - 1998/8/12/pubmed PY - 1998/8/12/medline PY - 1998/8/12/entrez SP - 348 EP - 52 JF - Journal of endocrinological investigation JO - J Endocrinol Invest VL - 21 IS - 6 N2 - The aim of this study was to compare the clinical efficacy and safety of low dose cyproterone acetate-estrogen combination (Diane) and the 5 alpha-reductase inhibitor finasteride in the treatment of hirsutism. Fourty-two women with hirsutism were included in the study. Twenty-one patients treated with cyproterone acetate (CPA) 2 mg and ethinyl estradiol (E) 35 micrograms daily on days 5-25 of the menstrual cycle, 21 with finasteride 5 mg daily. Hirsutism score, hormone levels, multiscreen blood chemistry and side effects were evaluated at three-monthly intervals for 9 months. A significant decrease in hirsutism score as compared to baseline was observed after 9 months with either CPA + E (Diane) (mean +/- SE, 15.81 +/- 1.19 vs 8.38 +/- 1.21) or finasteride treatment (17.81 +/- 1.05 vs 10.86 +/- 0.91) (p < 0.0005). The reductions in hirsutism scores (mean% +/- SE) were 14.23 +/- 2.29 vs 19.77 +/- 2.22 (p < 0.05) at 3, 40.23 +/- 4.58 vs 29.49 +/- 2.69 (p < 0.02) at 6 and 50.99 +/- 4.13 vs 39.87 +/- 3.30 (p < 0.02) at 9 months in CPA + E and finasteride groups, respectively. No significant changes were observed in hormone levels during finasteride treatment. Serum free testosterone significantly decreased at the third month of treatment, and remained suppressed for the duration of treatment in CPA + E group. DHEAS levels also decreased significantly after 6 and 9 months of therapy with CPA + E. SHBG significantly increased during CPA + E treatment. We conclude that both drugs are effective and well tolerated, but CPA + E appears to be more effective than 5 alpha-reductase inhibitor finasteride in long-term treatment of hirsute women. Diane is also a cost-effective drug. SN - 0391-4097 UR - https://www.unboundmedicine.com/medline/citation/9699125/Comparison_of_cyproterone_acetate_plus_ethinyl_estradiol_and_finasteride_in_the_treatment_of_hirsutism_ DB - PRIME DP - Unbound Medicine ER -